N U V I L E X (OTCQB: NVLX) recorded two key outcomes from its 2 independent Phase II clinical trials in patients with complex, inoperable pancreatic cancer.
1. The survival rate was greater than that of the recent gold standard and that of other competitors in clinical trials
2. The whole side-effect profile was low with Nuvilex’s treatment’
Researching more into those survival rate results:
At the time N U V I L E X’s clinical trials were conducted, Gemzar’s historical data gave patients a average survival time of five and a half months; where, N U V I L E X’s treatment during the 2 clinical trials lead to a average survival time of eleven months. Furthermore, the results demonstrated no grave or significant side effects.
The use of research materials issued by the author is done at your own risk. You are encouraged to do your own research before making any investment decision in regards to the secu rity discussed herein. The author has not been rewarded by any entity in connection with the disbursement of these materials. You should presume that as of the date of this report or letter, the author, possibly along with or through our owners, affiliates, employees and/or consultants, (communally referred to as the author) has a position in all company shares (and/or options of the shares) covered herein that is consistent with the position set forth in our report. In connection with NVLX, the author has taken a long position. Following the disbursement of any report or letter, the author plans to continue engaging in trnsactns in the security covered herein, and we may be long, short, and/or neutral at any time hereafter regardless of our initial position and we preserve the right to procure or trade all or part of our position at any time without notice. This practice could end in our trading securities at any time before, during, and/or after the disbursement of this report. Full Disclaimer
260 Madison Ave., 8th Fl., New York, New York 10016United States